Navigating Treatment Options in Low-Risk Myelodysplastic Syndromes
This video explores the current treatment landscape for lower-risk MDS patients, including the various agents and sequencing strategies employed to best optimize outcomes.
With advances in the understanding of myelodysplastic syndromes (MDS), both in the pathogenesis and biology of the disease, and with newer treatments and methods of supportive care, survival of patients with MDS has markedly improved.
In this video, Valeria Santini, MD, of the University of Florence in Italy, explores the current treatment landscape for lower-risk MDS patients, including the various agents and sequencing strategies employed to best optimize outcomes.
Santini also discusses treatment decisions based on molecular alterations and when experimental therapies might be most appropriate.
Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations
July 30th 2025Researchers have found that donor age is a key determinant of outcomes in hematopoietic cell transplantation, with younger donors associated with significantly better survival and lower rates of GVHD.
